CN110494435A - 氮杂环丁烷衍生物的固体形式及其制备方法和用途 - Google Patents

氮杂环丁烷衍生物的固体形式及其制备方法和用途 Download PDF

Info

Publication number
CN110494435A
CN110494435A CN201880023346.XA CN201880023346A CN110494435A CN 110494435 A CN110494435 A CN 110494435A CN 201880023346 A CN201880023346 A CN 201880023346A CN 110494435 A CN110494435 A CN 110494435A
Authority
CN
China
Prior art keywords
solvent
compound
formula
crystal
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880023346.XA
Other languages
English (en)
Other versions
CN110494435B (zh
Inventor
葛建华
韩增影
陈逢春
焦仕虎
张红
张萍
王利春
王晶翼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Original Assignee
Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Kelun Biotech Biopharmaceutical Co Ltd filed Critical Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Publication of CN110494435A publication Critical patent/CN110494435A/zh
Application granted granted Critical
Publication of CN110494435B publication Critical patent/CN110494435B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Description

PCT国内申请，说明书已公开。

Claims (11)

  1. PCT国内申请，权利要求书已公开。
CN201880023346.XA 2017-06-07 2018-05-28 氮杂环丁烷衍生物的固体形式及其制备方法和用途 Active CN110494435B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2017104217711 2017-06-07
CN201710421771 2017-06-07
PCT/CN2018/088645 WO2018223859A1 (zh) 2017-06-07 2018-05-28 氮杂环丁烷衍生物的固体形式及其制备方法和用途

Publications (2)

Publication Number Publication Date
CN110494435A true CN110494435A (zh) 2019-11-22
CN110494435B CN110494435B (zh) 2022-02-15

Family

ID=64565728

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880023346.XA Active CN110494435B (zh) 2017-06-07 2018-05-28 氮杂环丁烷衍生物的固体形式及其制备方法和用途

Country Status (7)

Country Link
US (1) US11066403B2 (zh)
EP (1) EP3636647B1 (zh)
JP (1) JP7120505B2 (zh)
CN (1) CN110494435B (zh)
DK (1) DK3636647T3 (zh)
ES (1) ES2937823T3 (zh)
WO (1) WO2018223859A1 (zh)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010039939A1 (en) * 2008-10-02 2010-04-08 Incyte Corporation Janus kinase inhibitors for treatment of dry eye and other eye related diseases
CN102026999A (zh) * 2008-03-11 2011-04-20 因塞特公司 作为jak抑制剂的氮杂环丁烷和环丁烷衍生物
WO2015166434A1 (en) * 2014-05-01 2015-11-05 Sun Pharmaceutical Industries Limited Crystalline form of baricitinib
WO2017082759A1 (ru) * 2015-11-13 2017-05-18 Акционерное Общество "Р-Фарм" (Ао "Р-Фарм") {3-[(7н-пирролo[2,3-d]пиримидин-4-ил)-азолил]азетидин-3-ил}-ацетонитрилы в качестве ингибиторов янус киназ

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7888330B2 (en) 2005-11-09 2011-02-15 Wayne State University Phosphoramidate derivatives of FAU
US20130310340A1 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
EP3183253B1 (en) 2014-08-21 2018-06-27 ratiopharm GmbH Salt of (r)-3-(4-(7h-pyrrolo [2,3-d]pyrimidin-4-yl)-lh-pyrazol-l-yl)-3-cyclopentylpropanenitrile with benzenesulfonic acid
CZ2014773A3 (cs) 2014-11-10 2016-05-18 Zentiva, K.S. Soli (3R)-3-cyklopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propannitrilu
WO2016141891A1 (zh) 2015-03-11 2016-09-15 苏州晶云药物科技有限公司 Jak抑制剂的晶型及其制备方法
CZ2015496A3 (cs) 2015-07-14 2017-01-25 Zentiva, K.S. Krystalické formy solí (3R)-3-cyklopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propannitrilu a jejich příprava
EP3360878B9 (en) 2015-12-11 2021-05-05 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Azetidine derivative, preparation method therefor, and use thereof
HU230931B1 (hu) 2016-01-21 2019-04-29 Egis Gyógyszergyár Zrt. Baricitinib sók
CZ201629A3 (cs) 2016-01-22 2017-08-02 Zentiva, K.S. Krystalické modifikace solí (3R)-3-cyklopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propannitrilu a způsoby jejich přípravy

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102026999A (zh) * 2008-03-11 2011-04-20 因塞特公司 作为jak抑制剂的氮杂环丁烷和环丁烷衍生物
WO2010039939A1 (en) * 2008-10-02 2010-04-08 Incyte Corporation Janus kinase inhibitors for treatment of dry eye and other eye related diseases
US20100113416A1 (en) * 2008-10-02 2010-05-06 Friedman Paul A Janus kinase inhibitors for treatment of dry eye and other eye related diseases
WO2015166434A1 (en) * 2014-05-01 2015-11-05 Sun Pharmaceutical Industries Limited Crystalline form of baricitinib
US20170204097A1 (en) * 2014-05-01 2017-07-20 Sun Pharmaceutical Industries Limited Crystalline form of baricitinib
WO2017082759A1 (ru) * 2015-11-13 2017-05-18 Акционерное Общество "Р-Фарм" (Ао "Р-Фарм") {3-[(7н-пирролo[2,3-d]пиримидин-4-ил)-азолил]азетидин-3-ил}-ацетонитрилы в качестве ингибиторов янус киназ

Also Published As

Publication number Publication date
JP7120505B2 (ja) 2022-08-17
US20200039978A1 (en) 2020-02-06
EP3636647B1 (en) 2023-01-11
US11066403B2 (en) 2021-07-20
ES2937823T3 (es) 2023-03-31
WO2018223859A1 (zh) 2018-12-13
EP3636647A1 (en) 2020-04-15
CN110494435B (zh) 2022-02-15
EP3636647A4 (en) 2021-03-10
DK3636647T3 (da) 2023-02-06
JP2020522462A (ja) 2020-07-30

Similar Documents

Publication Publication Date Title
EA032596B1 (ru) Соли, способ их получения и их применение для лечения воспалительных заболеваний
US10626118B2 (en) Pyrrolopyrimidine crystal for preparing JAK inhibitor
JP2022137223A (ja) セニクリビロクメシレートの固体形態及びセニクリビロクメシレートの固体形態を製造するプロセス
US20180282310A1 (en) Forms and compositions of biaryl inhibitors of bruton's tyrosine kinase
WO2017135471A1 (ja) α４β７インテグリン阻害剤
US20220144843A1 (en) Aminonorbornane derivative and manufacture method therefor and use thereof
CN108349974A (zh) 一种取代的吡啶酰胺类化合物及其应用
US10118911B2 (en) P-toluenesulfonate for MEK kinase inhibitor, and crystal form thereof and preparation method therefor
JP2023024729A (ja) ヤヌスキナーゼ阻害剤の結晶形
US11155523B2 (en) Biphenyl compound as CCR2/CCR5 receptor antagonist
KR102442536B1 (ko) 리나글립틴 결정형 및 이의 제조방법
TW201733992A (zh) 製備經取代５，６－二氫－６－苯基苯并［ｆ］異喹啉－２－胺之方法
US20220204475A1 (en) Solid form of diaminopyrimidine compound or hydrate thereof, preparation method therefor, and application thereof
CN110494435B (zh) 氮杂环丁烷衍生物的固体形式及其制备方法和用途
JP6873534B1 (ja) １，３，５−トリアジン誘導体またはその溶媒和物の結晶およびその製造方法
CN111566102B (zh) 作为激活素受体样激酶抑制剂的取代的吡咯并吡啶
CN111630048B (zh) 脒类和胍类衍生物、其制备方法及其在医药上的应用
CN112457296A (zh) 嘧啶类化合物及其制备方法
CN112154144A (zh) 一种1,2,4-三嗪-3-胺类衍生物的晶型及制备方法
US20200308103A1 (en) Novel crystals of hydroxamic acid derivative, production method thereof, and pharmaceutical composition
CN110903291B (zh) 一种杂芳基并[4,3-c]嘧啶-5-胺类衍生物的盐、盐的晶型及制备方法
CN112334473B (zh) 一种杂芳基并[4,3-c]嘧啶-5-胺类衍生物的晶型及制备方法
WO2024099403A1 (zh) 一种具有软药性质的硫醚类化合物、药物组合物及其用途
US20230242522A1 (en) Salt of tetrahydroisoquinoline derivative, preparation method therefor, and medical use thereof
KR20220159457A (ko) Fgfr4 억제제의 염 형태, 결정 형태 및 그 용도

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40015157

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant